Member Info for ace2326

What now seems evident is the market assumes the new product lines have no perceived value.

The MCAP is literally beginning to align 1:1 with declared cash in the bank

Dixie you’re opening new threads rather than replying inside one. If you scroll down to the message stream where you want to reply, and hit reply. Rather than using the post message button and putting Jamrock as the subject lol

I appreciate your positivity I really do.

But the share price is absolutely 1.10-1.25

Hard to do that Hotchip with the bones of £30k invested. Believing someone is going to actual market the items they promised to deliver. And assuming they would actually sell some of them.

Feel really disillusioned.

Bid 1.10
Ask 1.25
Products not launched
No new marketing strategy anyone can see
Distribution networks unannounced
Q1 ending, entering Q2
Radio silence

This is outrageous.

ps. Yada Yada Jam tomorrow is what my dad says when shares aren’t going anywhere but have a narrative of this amazing thing down the road

wasn’t a purposeful pun on your user name lol

Jamrock, I’m heavily invested here by my modest fortunes. 5 figures, it’s an awful lot of money to me. Nobody wants this share to go beyond 3p onwards more than me. (Except perhaps you lol) But for the sake of the conversation on our share, I have to try give balance.

Who is buying out MHC? I’d argue a larger competitor would be paying for the email database and customer data more than the products that haven’t sold, nor the covid tests that may or may not have a life span, whose impressive revenue probably won’t justify a buyout with the profit it actually generates.

I was majorly impressed with the journey to acquisition, to part of the covid approved, to the revenue, to the announcement of exciting new diversification. But respect is earned and then must be maintained.

I can not respect the delays, that lead to launching our product late, overshadowed by cost of living news. I can not respect the marketing efforts and lack of sales. I can’t agree with words like “prudent management and execution”.

They’ve tapped into something that works well, and are deciding to ostrich with heads in the sand with that. Yes the income has been used to diversify, but only previous customers will know about them via emails.

If they are pushing them hard exclusively via marketing emails, and are about to push another half dozen again, I would be anticipating a heavy unsubscribe percentage. Which will devalue the database.

The fact is they are not delivering and executing on the things you’ve said, The things that at the time convinced me to average down, repeatedly to now tie up well over 5 figures of my money for 2 years. (Fifth of a decade)

My money has now moved to being worth over half its total value. Which is ridiculous! We haven’t had an ODX GDR scenario, in fact the OPPOSITE!

I did not invest in this, with the expectation that products would arrive potentially overpriced, under advertised, under marketed and late. To focus on releasing another half dozen without working out how to sell the first half dozen, is unhinged. And this half arzed effort is being reflected in the share price.

At this stage I’d be expecting regular RNS announcing sales partnerships, daily social media / PR posts, social media advertising. The reality is a small team of 12 up in cardiff, including a Chief Digital Officer likely on 6 figure salary, who clearly has more experience with the fluff generated in his navel, than he is with representing us nationally.

I hope MHC read forums and take our thoughts into consideration. The MHC board is all a bit too nice, and recycled positives about revenue and the future.

Yada Yada Jam Tomorrow. Let’s have some accountability and pro active behaviour that got the company to this good position it finds itself in to begin with.

In an example:

TLSA is sat at $0.60c or so. It needs to get above $1 or is in trouble with its Nasdaq listing. The board need to feed news through to get above $1 for 10 days or face delisting, the other option is reverse split.

The BOD have to take action here, their decisions, their release of RNS and so on will directly effect, or at least attempt to effect the share price. Knowingly and willingly.

So to say the BOD don’t have a responsibility toward shareholder value, the share price isn’t just a position I find frustrating, I also find it insulting. Share price should be of massive consequence to the BOD, otherwise what is the point. We aren’t all invested here, or processing £22m worth of covid tests out of the goodness of our hearts.

Or is that what you’re saying?

or so* (shares at stake)

what they will be doing differently to sell those*

I wouldn’t say we are “making millions”. The revenue is sexy sure, but the cash balance is pretty much sideways.

I’m aware that’s healthy, but all eyes now point toward coming up to 12 months with zero professional marketing strategy or advertising implemented for non covid products.

We disagree about the BOD responsibility to share price, meanwhile I’d like to point out we are significantly lower than we were this time a year ago.

You’ve already mentioned a share above that failed to redirect its strategy in regards to covid and drop off a cliff in the share price. I can think of others. If we don’t get the marketing going, I’d like to see your bullishness for this with ten million or show shares at stake.

Someone’s got to be responsible for 1.25p. And for me it’s whoever is (not) sending out RNS. Who is not delivering partnerships and marketing or sales deals and who continues to write said RNS we get occasionally, in such a way that ignores the elephant in the room with regards to the necessity that the new products are a success. Who is now late, with no apology or explanation as to additional products, who has not informed us of what different if at all that will be doing to sell those.

If there isn’t a responsibility there to share price, explain why the decline appears completely in line with the lack of news flow and progress with what I described above.

If you don’t think there’s a relationship between the decisions makers of a company itself, and the shareholders, in terms of decisions and actions that provide shareholder value, then we can agree to disagree.

It’s their responsibility to develop and execute a marketing plan, within a year, for a group of products that clearly aren’t selling.

Because it’s their responsibility to show the market that their turnover and profitability is future proof. This is why the share isn’t moving anywhere, that major detail has not been clearly presented, with evidence.

Double on the bid would give me my money back in full. Completely disillusioned with the point of investing in the first place to be sat 50% down on this revenue and cash.

BOD has done absolutely nothing for SH value, marketing the new products or sticking to deadlines.

Fed up. Just want ALL my money back and not a penny less. It’s been a total waste of my time and money tied up for a fifth of a decade.

@Jam

Tbh 11% isn’t too bad compared to spreads we have seen lol

Thanks Karlvonwise

I just feel I’m going to have to spend £7.5k at current prices to see 2p to then make any money on a rise to 2.5p or Breakeven.

Just fed up that shares don’t make money anymore. And all seemingly need bailing out by averaging down.

It’s just not the point of investing. And when a share that has good news does what this does this morning, it just leaves you feeling completely disillusioned

@karlvonwise

I don’t mean to be a Debbie downer, but I do feel my sentiments are backed up by the share price this morning. Down nearly 10% on £22m turnover and nearly £8m in the bank.

Bid 1.30, Ask 1.50, are we supposed to pretend that’s acceptable. There’s been no growth, the share price hasn’t seen 3p for what feels like 2 years now. A fifth of a decade.

We are supposed to pretend that’s positive and acceptable. I say no.

@Jamrock sorry I really do appreciate you as an Mhc Investor and a poster but I’ve got to say I totally disagree with you.

Bottom line, any company and BOD is supposed
to be there for its shareholders. Of course they should be obligated to support the share price.

We have bought shares and done our part, I’m 7 figures in
Shares, and 5 figures in money invested. I want ROI, to see my money grow. That’s the absolute bottom line reason any of us are here. (Aware you’re even more heavily invested, but I’m sure there’s comfort with an average below 2p)

The shares being cheap are nothing to do with people desperate to sell for a tax bill. It’s cheap because we’ve been at best sideways for a calendar year.

You are totally satisfied, then I’d say your standards are too low right now. There’s nothing satisfactory regards the share price, or the new product delay, or the existing products marketing and sales.

No Jam, time to support the share price.

We had about this much money in cash in a previous update. What are we doing with it if not chasing acquisitions, or marketing?

Otherwise we are moving sideways and leaning on covid going forward to simply stand still.

If getting the products into a retailer resulted in a breakeven or small loss, and it had a positive impact on share price and or brand awareness, I’d be happy.

Right now just feels like we are sitting on her hands. And the share price reflects that.

@jamrock

I’m delighted covid sales have not dried up as I’d be uncomfortable with where we would find ourselves without it.

Don’t get me wrong £22m revenue and shy of £8m in the bank is AMAZING rns news as ever from MHC.

But bottom line is the market for the last year has been firmly disinterested with this share should it solely rely on covid, has it not?

My frustration is with that being ignored, which ties in with Penny saying she doesn’t care about SP previously. Unfortunately as a PI, I’m here to make money grow, and to do that SP needs to go up.

That simply isn’t going to happen without the company getting a foothold in the wellness market. And the importance of marketing being skimmed over, as is the importance of non covid growth, that leaves us reliant on covid.

What happens if that well dries up? Mentioning new products coming soon isn’t anything to get the market excited about if they are going to have the same impact as the first lot had. And it isn’t because they are dud products, it’s because the best we’ve come up with is a few Mail chimp emails.

@jyee, scharnhorst, to clarify I meant *existing products*

Yes I did read it twice, and what I read was more or less “after 6-8 months from launch of the new range of products, we are still hugely reliant on the covid testing”

It’s a positively written RNS, and the turnover is great. However:

- can’t deny the attention to the existing wellness products is minimal and brushed over and has been for the last 3-4 drawn out/delayed RNS

- it’s clear it’s still solely reliant on covid

- whilst cash position is very healthy, there’s no mention of any acquisitions, investment in marketing, anything promising mentioned regarding selling in stores.

@Karlvonwise, I’m extremely critical because I’m invested well over 1.5 years, possibly 2 now, and the SP is worse now than it was a year ago.

The market perceives the share as a covid play, the plan was to evolve from this. It would be ignorant to deny the attention to marketing and selling the wellness products completely marries up with the attention they’ve been given in the last half dozen RNS because it does.

It’s an elephant in the room the BOD is avoiding addressing.

Absolutely ZERO mention of the wellness products. The RNS may as well be written as though they don’t exist.

Turnover very impressive, cash in the bank the same as last
update so haven’t depleted, but haven’t increased it either. No mention of acquisitions, and the cash off the back of the revenue, sort of confirms no money on marketing, no income from other products has happened.